参芪糖肾方对气阴两虚证糖尿病肾病患者临床疗效及血清肾纤维化标志物的影响  

Effects of Shenqi Tangshen Prescription on Clinical Efficacy and Serum Renal Fibrosis Markers in Patients with Diabetic Kidney Disease with Qi-Yin Deficiency Syndrome

作　　者：潘军[1] 宣建宗 丁仁华 吴亮亮 刘源 王义元 张海银 董建睿 PAN Jun;XUAN Jianzong;DING Renhua;WU Liangliang;LIU Yuan;WANG Yiyuan;ZHANG Haiyin;DONG Jianrui(Department of Nephrology,Tianchang Hospital of Traditional Chinese Medicine,Tianchang,Anhui 239300,China)

机构地区：[1]天长市中医院肾病科,安徽天长239300

出　　处：《临床误诊误治》2025年第1期96-100,共5页Clinical Misdiagnosis & Mistherapy

基　　金：滁州市科技计划指导类项目(2023ZD001);安徽省中医药高水平传承人才支持项目[皖中医药发展秘(2024)1号];2024年度滁州市临床重点专科建设项目[滁卫健函(2024)47号]。

摘　　要：目的探讨气阴两虚证糖尿病肾病(DKD)患者应用参芪糖肾方的疗效。方法选取2021年6月至2024年6月收治的气阴两虚证DKD患者58例,按照随机数字表法分为观察组和对照组,每组29例,观察组采用常规治疗联合参芪糖肾方治疗,对照组采用常规治疗,比较2组临床疗效、糖代谢指标、肾功能指标、血清肾纤维化标志物。结果观察组总有效率高于对照组(P<0.05)。治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组(P<0.05)。治疗后,观察组估算肾小球滤过率高于对照组,尿白蛋白与肌酐比值低于对照组(P<0.05)。治疗后,观察组血清转化生长因子-β1、结缔组织生长因子均低于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论气阴两虚证DKD患者联合应用参芪糖肾方治疗能够改善糖代谢及肾功能,在改善血清肾纤维化标志物及肾微血管病变方面也有优势,且安全性良好,临床疗效显著。Objective To investigate the effect of Shenqi Tangshen prescription on diabetic kidney disease(DKD)with Qi-Yin deficiency syndrome.Methods Fifty-eight DKD patients with Qi-Yin deficiency syndrome treated from June 2021 to June 2024 were selected and divided into observation group(n=29)and control group(n=29)according to random number table method.The observation group was treated with conventional treatment combined with Shenqi Tangshen prescription,and the control group was treated with conventional treatment.Clinical efficacy,glucose metabolism indexes,renal function indexes and serum renal fibrosis markers were compared between the two groups.Results The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in observation group were lower than those in control group(P<0.05).After treatment,the estimated glomerular filtration rate of observation group was higher than that of control group,whereas the urinary albumin-to-creatinine ratio was lower than that of control group(P<0.05).After treatment,the serum transforming growth factorβ1 and connective tissue growth factor in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Shenqi Tangshen prescription for DKD patients with Qi-Yin deficiency syndrome can improve glucose metabolism and renal function,and has advantages in improving serum renal fibrosis markers and renal microvascular lesions,with good safety and significant clinical efficacy.

关 键 词：糖尿病肾病 参芪糖肾方 气阴两虚 空腹血糖 糖化血红蛋白 肾小球滤过率 转化生长因子-β1 结缔组织生长因子 

分 类 号：R587.2[医药卫生—内分泌]